Superpower peptides available for pre-order. Get first access.
Not FDA-approved
Brain & sleep
What benefits of semax are under study?
Semax benefits under study include memory, stroke recovery, stress-related mood, and optic nerve health, mostly in rats. See what small human studies found.
Quick answer
Semax is not FDA-approved and has no established labeled route. Researchers have studied it for memory and learning, stroke recovery, stress-related mood, and optic nerve disease, mostly in rats. In one rat stroke study, damage was about 20% smaller after intranasal Semax. Human studies are small and mostly published in Russian, including one stroke study of 110 rehabilitation patients. FDA's 2026 review found insufficient evidence of effectiveness for reduced brain blood flow, migraine, and trigeminal neuralgia.
- Published
- November 4, 2026
- Last updated
- November 4, 2026
Benefits and uses researchers are exploring
Researchers are studying Semax for memory, stroke recovery, stress-related mood and anxiety, and optic nerve disease. Most published findings come from laboratory and animal research. The human studies are small1 and mostly published in Russian.
Semax is a synthetic peptide of seven amino acids1, modeled on ACTH(4-10), a fragment of adrenocorticotropic hormone. It lacks that hormone's action on the adrenal glands. Interest centers on Semax as a nootropic, a compound studied for effects on thinking.
Semax, cognition, and memory
In rats, intranasal Semax raised BDNF (brain-derived neurotrophic factor) in the basal forebrain three hours later2. A single dose raised hippocampal BDNF up to 1.4-fold3 in another rat study. Those rats also did better on a learning task3.
A brain-imaging study of 24 healthy adults4 gave 14 intranasal Semax and 10 placebo. No memory test, randomization, or blinding was reported. An earlier study of 19 healthy men1 reported better work efficiency 20 to 24 hours5 after intranasal Semax.
Semax and stroke recovery
Semax has been studied after ischemic stroke in rats, and in Russian patient studies reporting faster recovery6. Those patient studies describe no randomization or blinding.
- Rat stroke models: After a cortex stroke, rats given intranasal Semax for six days had damage about 20% smaller1 and better recall of a learned task7. Injected Semax after artery blockage shifted immune and vascular gene activity8.
- Acute stroke patients: Authors compared 30 patients on Semax plus intensive therapy with 80 on conventional therapy. They reported some effect on motor recovery pace9.
- Rehabilitation patients: Among 110 adults months after stroke, those given Semax had higher blood BDNF and better daily-living scores6 than those without.
No larger controlled trial has repeated these patient results.
Semax, mood, and anxiety in stress research
Semax reduced depression- and anxiety-like behavior in rodents1 under stress. One meeting abstract covers adolescents with depression.
In male rats under chronic unpredictable stress, daily injected Semax countered lost preference for sugar water10. That loss signals lost pleasure. It also reduced adrenal enlargement and a stress-linked drop in hippocampal BDNF. Forced swim test results did not change.
In male rats injected before a short restraint stress, stress-related behavior changes were smaller11.
The abstract's 120 adolescents, aged 12 to 141, also received talk therapy and low-power electromagnetic therapy. That mix leaves the effect of Semax unclear.
Semax and optic nerve health in published studies
In rats, tracer-labeled Semax given intranasally reached the brain and the eyes12. The study measured no effect on vision.
Patients with vascular, toxic, or inflammatory optic nerve disease received add-on Semax. It came as nasal drops or by nasal electrophoresis13, an electric-current delivery. The authors reported faster recovery and better sharpness of vision14, visual field, and color vision than controls. A glaucoma report described better results on electrical eye tests15 for a regimen including Semax.
Neither report gave patient numbers or described randomization or blinding.
What has human research found on Semax benefits?
FDA's 2026 review found insufficient evidence of effectiveness1 for three uses. Those were reduced brain blood flow, migraine, and trigeminal neuralgia (facial nerve pain). It set aside the Russian stroke papers, which had no English full text.
| Research area | Laboratory and animal findings | Human research |
| Cognition and memory | BDNF and learning rose in rats | A few small healthy-adult studies |
| Stroke recovery | Smaller damage, better recall in rats | Small Russian studies, design unclear |
| Mood and anxiety | Less stress-related behavior in rats | 1 adolescent meeting abstract |
| Optic nerve | Reached rat eyes after nasal dosing | Small Russian add-on reports |
| Safety | No standard toxicity studies found | No drug-level studies; 1 adverse-event report |
Semax is not named on the 2026 World Anti-Doping Agency (WADA) Prohibited List16, which also bans unnamed substances with a similar chemical structure or effect to listed ones. Athletes subject to drug testing should check with their anti-doping organization and league before using Semax.
Getting Semax in 2026
Superpower will offer Semax formulated in FDA-registered facilities in the US, backed by third-party lab testing, and distributed from US-licensed pharmacies. Licensed clinicians will decide whether Semax fits each person's health care. The Superpower peptide waitlist is open now.
Semax has not received FDA approval as a drug. In October 2026, the Department of Health and Human Services stated it does not intend to take enforcement action17 against state-licensed pharmacies compounding specific peptides while the 503A Bulks List, the list of ingredients pharmacies may use in compounding, is being finalized. Semax is one of six peptides the interim policy covers18, under conditions that include FDA-registered ingredient sources and a patient-specific prescription. A July 2026 FDA advisory committee recommendation to add Semax to the list19 preceded the policy, and rulemaking continues.